GALLIUM CITRATE GA 67 INJECTION DIN 02329816
Health Canada record
| Active ingredient(s) | GALLIUM CITRATE GA 67 2 MCI |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | SCHEDULE C |
| Class | Radiopharmaceutical |
| ATC | |
| Original market date | |
| Current status date | 29-Sep-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
Bristol-Myers Squibb Canada — licence 100100, currently licensed, last inspection rating C (2026-03-18).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing GALLIUM CITRATE GA
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02327813 | GALLIUM (GA67) CITRATE INJECTION | CURIUM CANADA INC | Solution | GALLIUM CITRATE GA 67 74 MBq | Marketed |
| 02327759 | GALLIUM | LANTHEUS MI CANADA INC | Solution | GALLIUM CITRATE GA 67 74 MBq | Cancelled Post Market |
International API supply for GALLIUM CITRATE GA
0 active FDA Drug Master Files.
Request a quote for GALLIUM CITRATE GA 67 INJECTION